Reviva announces $3M registered direct offering of 1.9M shares and warrants at $1.58/unit

REVIVA PHARMACEUTICALS HOLDINGS, INC.

Sold 1,898,734 shares and warrants at $1.58/unit; warrants exercisable at $1.455 for 5 years.
Net proceeds ~$3.0M; funds Phase 3 RECOVER-2 trial and working capital.
Existing Nov 2023 warrants (1,365,854 shares, $5.00 exercise) amended to $1.455, extended 5 years.
H.C. Wainwright placement agent; cash fee 6% of gross proceeds.
Closing expected May 29, 2024, subject to customary conditions.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.